Robert Dobrzynski, MD
Endocrinology, Diabetes & Metabolism · Providence, RINPI 1598863599
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $223,378 of the $244,929 with a category attached, or 91.2%. 17 manufacturers reported payments, led by Novo Nordisk at 49.6% of the total. Among endocrinology, diabetes & metabolism clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 277 payments — averaging $884.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$121K
- Dexcom, Inc.$43K
- Johnson & Johnson$24K
- AstraZeneca$23K
- Bayer$22K
- Abbott$7K
- plus $5K from 11 others
What the payments were for
- Consulting fees$4,5372%
- Speaking & faculty fees$223,37891%
- Travel & lodging$8,0983%
- Food & beverage$8,8304%
- Education$870%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 117 | $121,375 |
| Dexcom, Inc. | 39 | $43,397 |
| Johnson & Johnson | 24 | $23,645 |
| AstraZeneca | 30 | $22,956 |
| Bayer | 21 | $21,691 |
| Abbott | 13 | $7,135 |
| Ascensia Diabetes Care US Inc. | 6 | $3,540 |
| Xeris Pharmaceuticals, Inc. | 1 | $690 |
| Amgen(2 entities) | 8 | $152 |
| AbbVie | 8 | $142 |
| Sanofi-aventis U.S. LLC | 3 | $45 |
| Mannkind Corporation | 1 | $43 |
| Sequel Med Tech, LLC | 2 | $41 |
| Lilly USA, LLC | 1 | $27 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Ascendis Pharma Endocrinology Inc | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$56,947
- DEXCOM G7 GSS (161)$39,132
- RYBELSUS$35,725
- INVOKANA$23,151
- FARXIGA$22,603
- Kerendia$21,310
- DEXCOM STELO GLUCOSE BIOSENSOR$14,027
- Tresiba$5,018
- DEXCOM G6 TRANSMITTER$3,830
- FreeStyle Libre Pro$3,538
- FreeStyle Libre$3,525
- EVERSENSE E3 SENSOR KIT - RETAIL$3,476
- GVOKE PFS$690
How this compares
$244,929 in reported general payments places this provider in the 95th percentile of 30 endocrinology, diabetes & metabolism providers in Rhode Island.
See all endocrinology, diabetes & metabolism providers in Rhode Island →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 1,203 | $1,314,415 |
| JardianceEmpagliflozin | 681 | $590,525 |
| FarxigaDapagliflozin Propanediol | 671 | $512,746 |
| TrulicityDulaglutide | 275 | $290,349 |
| LenvimaLenvatinib Mesylate | 11 | $268,147 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 357 | $253,006 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 171 | $199,066 |
| MounjaroTirzepatide | 146 | $178,120 |
| Tresiba Flextouch U-200Insulin Degludec | 116 | $159,666 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 190 | $120,346 |
| RybelsusSemaglutide | 100 | $117,311 |
| Humalog Kwikpen U-100Insulin Lispro | 355 | $100,439 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 56 | $85,265 |
| Tresiba Flextouch U-100Insulin Degludec | 107 | $77,339 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 444 | $77,266 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp, Tresiba, Novolog | $121,375 | $1,491,8291,404 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Humulin 70-30 | $27 | $535,709738 claims |
| AstraZenecaFarxiga | $22,956 | $512,746671 claims |
| Johnson & JohnsonInvokana | $23,645 | $47,49047 claims |
| AbbVieSynthroid | $142 | $42,170516 claims |
| BayerKerendia | $21,691 | $29,48434 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 30 endocrinology, diabetes & metabolism providers in Rhode Island.
Other endocrinology, diabetes & metabolism in Providence
- Robert SmithProvidence$80K
- Joseph TucciProvidence$30K
- Manchin ChangProvidence$878
- Roberto OrtizProvidence$598
- Daryl SelenProvidence$450
- Alicia WarnockProvidence$317
- Meghana KoletiProvidence$145
- Charles KahnProvidence$125
- David MacleanProvidence$121
- Frank D'alessandroNorth Providence$193K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.